Palvella Therapeutics, Inc. Derivative Liability, Current
Palvella Therapeutics, Inc. (PVLA) had Derivative Liability, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2026-08-04
- 2026-06-30: Derivative Liability, Current $0.00.
- 2026-03-31: Derivative Liability, Current $0.00.
- 2025-12-31: Derivative Liability, Current $2.20M.
- 2025-09-30: Derivative Liability, Current $2.22M.
| Period end | Derivative Liability, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.20M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $2.22M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.98M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.98M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.98M 10-K · filed 2026-03-31 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |